To determine the ability of EA to alter LEF-1, cyclin D1, fibronectin and Fzd5 transcript expression, CLL cells from three patients were treated with the drug for 16 h, and then analyzed by real-time PCR. Here, LEF1 is linked to B-cell chronic lymphocytic leukemia.